Clinical Trial Update: Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, dose response, and immunogenicity of the Measles Vaccine MVA mBN85B in healthy children aged 6 months to 6 years has completed.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles

Drugs mentioned

• Measles Vaccine MVA mBN85B

Snippet

Sponsor: Bavarian Nordic | Conditions: Measles | Phase 2 | Status: COMPLETED